Ivy League and Fellowship-trained, Board-certified Breast Imaging Radiologists specializing in advancing innovative breast imaging access.
At MammoTelerad, we partner with women's health medical practices to provide innovative breast imaging modalities at the point of care: breast QT, breast CT, ABUS, mammography and MRIs. We generate a lucrative additional revenue stream for women's health clinics while helping deliver accurate and timely early detection of breast cancer. This approach significantly reduces delays in breast cancer diagnosis, alleviates patient anxiety by eliminating long wait times, and provides clinically relevant information for effective patient management.
Our team of board-certified radiologists specialize in breast imaging and are certified to interpret multi-modality breast studies. We understand the importance of timely and accurate diagnoses, and we are committed to providing high-quality services to our patients and partnering clinicians. Our service allows clinicians to have confidence in diagnosing breast conditions.
Teleradiology: Our teleradiology platform utilizes state-of-the-art technology to securely transmit images and reports to our radiologists in real-time, allowing us to provide rapid turnaround times for our interpretations.
Instead of referring your patients for breast ultrasound imaging elsewhere, partner with us to provide expert breast care in your own practice. Enhance patient satisfaction, improve continuity of care, and create a valuable new service line—all while helping detect breast cancer earlier when it's most treatable. At Mammotelerad, we're transforming breast cancer detection by bringing the latest breast imaging modalities to women's health clinics.
✔ New lucrative revenue streams to your practice
✔ Accurate breast QT interpretations
✔ Accurate breast CT interpretations
✔ Regular mammograms, automated whole breast ultrasound (ABUS) and MRI interpretations
✔ Launch supplemental breast cancer screening programs for women with dense breast tissue or high cancer risk